Compare MCR & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCR | CCCC |
|---|---|---|
| Founded | 1989 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.3M | 240.3M |
| IPO Year | N/A | 2020 |
| Metric | MCR | CCCC |
|---|---|---|
| Price | $6.28 | $2.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 66.7K | ★ 1.7M |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | ★ 8.52% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | N/A | ★ $30,108,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.61 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.63 | $1.09 |
| 52 Week High | $6.70 | $4.22 |
| Indicator | MCR | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 42.03 | 48.53 |
| Support Level | $6.23 | $1.87 |
| Resistance Level | $6.29 | $2.33 |
| Average True Range (ATR) | 0.04 | 0.13 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 28.57 | 65.22 |
MFS Charter Income Trust is a United States-based closed-end fund. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests the assets in Debt Instruments, Corporate Bonds, U.S. Government Securities, Foreign Government Securities, Securitized Instruments, Derivatives, Principal Risks, Debt Management Risk, Investment Selection Risk, Interest Rate Risk, Credit Risk, Foreign Risks, Emerging Markets Risk, Currency Risk, Leveraging Risk, Operational and Cybersecurity Risk, Active and Frequent Trading, and etc of different market countries.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.